Dr. Xiaojun Zhang brings over 26 years of experience in drug discovery from target identification and validation, lead optimization to support of clinical development candidates. Prior to his appointment as Vice President of Chemistry at Degron Therapeutics, Dr. Zhang was Scientific Associate Director at Bristol Myers Squibb. There, he led a team to the advancement of several clinical candidates for the prevention of arterial thrombosis and for the treatment of heart failure. He is the inventor/co-inventor of over 20 issued small molecule patent applications, and has published over 30 scientific articles in peer-reviewed journals. He is a recognized expert in designing novel small molecule drugs and has presented at many scientific conferences throughout the United States.

Dr. Zhang received a BS from Wuhan University and a PhD in Organic Chemistry from the University of California, Los Angeles. He completed his postdoctoral training with Professor Ronald Breslow at Columbia University.